Highlights
KLSE: AHEALTH (7090)       APEX HEALTHCARE BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
3.55   0.00 (0.00%)  3.48 - 3.56  57,000
Trade this stock with 3 x trading limit. Find out more.

Financials


Market Cap: 1,687 Million

Market Cap 1,687 Million
NOSH 475 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 05-Jun-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 05-Jun-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 19-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 19-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   9.12%  |    0.71%

Annual (Unaudited) ( EPS: 11.10, P/E: 31.98 )

Revenue | NP to SH 688,786  |  52,750
RPS | P/RPS 144.94 Cent  |  2.45
EPS | P/E | EY 11.10 Cent  |  31.98  |  3.13%
DPS | DY | Payout % 3.67 Cent  |  1.03%  |  33.06%
NAPS | P/NAPS 0.89  |  3.98
YoY   -9.95%
NP Margin | ROE 7.66%  |  12.44%
F.Y. | Ann. Date 31-Dec-2019  |  19-Feb-2020

T4Q Result ( EPS: 11.71, P/E: 30.33 )

Revenue | NP to SH 707,786  |  55,631
RPS | P/RPS 148.94 Cent  |  2.38
EPS | P/E | EY 11.71 Cent  |  30.33  |  3.30%
DPS | DY | Payout % 3.67 Cent  |  1.03%  |  31.38%
NAPS | P/NAPS 0.96  |  3.72
QoQ | YoY   0.18%  |    0.15%
NP Margin | ROE 7.86%  |  12.25%
F.Y. | Ann. Date 30-Sep-2020  |  19-Nov-2020

Annualized Result ( EPS: 11.68, P/E: 30.40 )

Revenue | NP to SH 716,202  |  55,502
RPS | P/RPS 150.71 Cent  |  2.36
EPS | P/E | EY 11.68 Cent  |  30.40  |  3.29%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   1.27%  |    7.44%
NP Margin | ROE 7.75%  |  12.22%
F.Y. | Ann. Date 30-Sep-2020  |  19-Nov-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2020 19-Nov-2020 30-Sep-2020 3 537,152 51,773 41,638 41,627 8,041 454,102 19.32% 7.75% 9.17% 473,023 113.56 113.03 8.80 8.76 1.70 1.69 0.9600 0.96   51.90%   7.44% 30-Sep-2020 3.24 2.85 36.82 3.38 2.72% 0.52% 19-Nov-2020 3.60 3.17 40.91 3.75 2.44% 0.47%
31-Dec-2020 26-Aug-2020 30-Jun-2020 2 368,036 34,285 27,292 27,404 8,032 444,145 29.31% 7.42% 6.17% 472,495 77.89 77.44 5.80 5.77 1.70 1.69 0.9400 0.93   90.70%   11.29% 30-Jun-2020 2.80 3.59 48.28 2.98 2.07% 0.61% 26-Aug-2020 3.72 4.78 64.14 3.96 1.56% 0.46%
31-Dec-2020 21-May-2020 31-Mar-2020 1 193,308 17,944 14,362 14,370 - 438,661 - % 7.43% 3.28% 471,679 40.98 40.68 3.05 3.02 0.00 0.00 0.9300 0.92   -72.76%   26.06% 31-Mar-2020 2.11 5.15 69.26 2.27 1.44% 0.00% 21-May-2020 2.90 7.08 95.19 3.12 1.05% 0.00%
31-Dec-2019 19-Feb-2020 31-Dec-2019 4 688,786 66,334 52,772 52,750 17,438 424,170 33.06% 7.66% 12.44% 471,301 146.15 144.94 11.19 11.10 3.70 3.67 0.9000 0.89   36.14%   -9.95% 31-Dec-2019 2.24 1.53 20.01 2.49 5.00% 1.65% 19-Feb-2020 2.41 1.65 21.53 2.68 4.64% 1.54%
31-Dec-2019 21-Nov-2019 30-Sep-2019 3 518,152 47,850 38,766 38,746 8,011 409,992 20.68% 7.48% 9.45% 471,256 109.95 109.03 8.22 8.15 1.70 1.69 0.8700 0.86   57.36%   -7.26% 30-Sep-2019 2.18 1.98 26.51 2.51 3.77% 0.78% 21-Nov-2019 2.40 2.18 29.19 2.76 3.43% 0.71%
31-Dec-2019 21-Aug-2019 30-Jun-2019 2 337,499 30,726 24,644 24,623 8,008 405,125 32.52% 7.30% 6.08% 471,076 71.64 71.02 5.23 5.18 1.70 1.69 0.8600 0.85   116.01%   -8.40% 28-Jun-2019 2.17 3.03 41.52 2.52 2.41% 0.78% 21-Aug-2019 2.03 2.83 38.84 2.36 2.57% 0.84%
31-Dec-2019 23-May-2019 31-Mar-2019 1 178,229 14,543 11,414 11,399 - 392,099 - % 6.40% 2.91% 117,395 151.82 37.50 9.71 2.40 0.00 0.00 3.3400 0.83   -80.54%   -13.52% 29-Mar-2019 8.87 5.84 91.35 2.66 1.09% 0.00% 23-May-2019 8.60 5.66 88.57 2.57 1.13% 0.00%
31-Dec-2018 28-Feb-2019 31-Dec-2018 4 652,660 69,270 58,667 58,581 15,834 381,202 27.03% 8.99% 15.37% 117,293 556.44 137.34 49.94 12.33 13.50 3.33 3.2500 0.80   40.22%   31.76% 31-Dec-2018 7.80 1.40 15.62 2.40 6.40% 1.73% 28-Feb-2019 8.95 1.61 17.92 2.75 5.58% 1.51%
31-Dec-2018 15-Nov-2018 30-Sep-2018 3 489,599 52,531 41,864 41,777 7,616 365,595 18.23% 8.55% 11.43% 117,178 417.83 103.02 35.65 8.79 6.50 1.60 3.1200 0.77   55.42%   31.96% 28-Sep-2018 8.25 1.97 23.14 2.64 4.32% 0.79% 15-Nov-2018 8.10 1.94 22.72 2.60 4.40% 0.80%
31-Dec-2018 16-Aug-2018 30-Jun-2018 2 324,346 33,894 26,922 26,880 7,614 360,809 28.33% 8.30% 7.45% 117,146 276.87 68.25 22.95 5.66 6.50 1.60 3.0800 0.76   103.93%   31.84% 29-Jun-2018 6.79 2.45 29.59 2.20 3.38% 0.96% 16-Aug-2018 7.25 2.62 31.60 2.35 3.16% 0.90%
31-Dec-2018 24-May-2018 31-Mar-2018 1 168,400 16,526 13,221 13,181 - 356,123 - % 7.85% 3.70% 117,146 143.75 35.44 11.25 2.77 0.00 0.00 3.0400 0.75   -70.35%   30.62% 30-Mar-2018 5.48 3.81 48.70 1.80 2.05% 0.00% 24-May-2018 5.76 4.01 51.19 1.89 1.95% 0.00%
31-Dec-2017 22-Feb-2018 31-Dec-2017 4 620,264 56,047 44,488 44,459 14,057 343,237 31.62% 7.17% 12.95% 117,146 529.48 130.52 37.95 9.36 12.00 2.96 2.9300 0.72   40.44%   27.19% 29-Dec-2017 5.60 1.06 14.76 1.91 6.78% 2.14% 22-Feb-2018 4.90 0.93 12.91 1.67 7.75% 2.45%
31-Dec-2017 14-Nov-2017 30-Sep-2017 3 467,679 39,667 31,689 31,658 6,443 330,351 20.35% 6.78% 9.58% 117,146 399.23 98.41 27.02 6.66 5.50 1.36 2.8200 0.70   55.28%   12.27% 29-Sep-2017 5.10 1.28 18.87 1.81 5.30% 1.08% 14-Nov-2017 5.50 1.38 20.35 1.95 4.91% 1.00%
31-Dec-2017 16-Aug-2017 30-Jun-2017 2 309,949 26,365 20,399 20,388 6,443 325,665 31.60% 6.58% 6.26% 117,146 264.58 65.22 17.40 4.29 5.50 1.36 2.7800 0.69   102.04%   4.76% 30-Jun-2017 4.70 1.78 27.01 1.69 3.70% 1.17% 16-Aug-2017 4.74 1.79 27.24 1.71 3.67% 1.16%
31-Dec-2017 17-May-2017 31-Mar-2017 1 154,652 12,912 10,099 10,091 - 322,151 - % 6.53% 3.13% 117,146 132.02 32.54 8.61 2.12 0.00 0.00 2.7500 0.68   -71.13%   2.83% 31-Mar-2017 4.90 3.71 56.88 1.78 1.76% 0.00% 17-May-2017 4.70 3.56 54.56 1.71 1.83% 0.00%
31-Dec-2016 23-Feb-2017 31-Dec-2016 4 581,269 46,294 34,988 34,954 13,471 311,608 38.54% 6.02% 11.22% 117,146 496.19 122.31 29.84 7.36 11.50 2.83 2.6600 0.66   23.96%   2.10% 30-Dec-2016 4.30 0.87 14.41 1.62 6.94% 2.67% 23-Feb-2017 4.65 0.94 15.58 1.75 6.42% 2.47%
31-Dec-2016 15-Nov-2016 30-Sep-2016 3 437,123 36,215 28,222 28,198 - 301,065 - % 6.46% 9.37% 117,146 373.14 91.98 24.07 5.93 0.00 0.00 2.5700 0.63   44.89%   38.02% 30-Sep-2016 4.54 1.22 18.86 1.77 5.30% 0.00% 15-Nov-2016 4.60 1.23 19.11 1.79 5.23% 0.00%
31-Dec-2016 17-Aug-2016 30-Jun-2016 2 294,163 24,679 19,474 19,462 6,443 298,722 33.11% 6.62% 6.52% 117,146 251.11 61.90 16.61 4.10 5.50 1.36 2.5500 0.63   98.33%   29.32% 30-Jun-2016 3.89 1.55 23.41 1.53 4.27% 1.41% 17-Aug-2016 3.82 1.52 22.99 1.50 4.35% 1.44%
31-Dec-2016 18-May-2016 31-Mar-2016 1 147,478 12,366 9,819 9,813 - 296,379 - % 6.66% 3.31% 117,146 125.89 31.03 8.38 2.06 0.00 0.00 2.5300 0.62   -71.34%   16.19% 31-Mar-2016 3.73 2.96 44.53 1.47 2.25% 0.00% 18-May-2016 3.94 3.13 47.04 1.56 2.13% 0.00%
31-Dec-2015 25-Feb-2016 31-Dec-2015 4 526,859 45,842 34,263 34,236 12,886 288,179 37.64% 6.50% 11.88% 117,146 449.75 110.86 29.23 7.20 11.00 2.71 2.4600 0.61   67.58%   0.76% 31-Dec-2015 3.60 0.80 12.32 1.46 8.12% 3.06% 25-Feb-2016 3.41 0.76 11.67 1.39 8.57% 3.23%
31-Dec-2015 26-Nov-2015 30-Sep-2015 3 392,611 28,677 20,436 20,430 - 274,121 - % 5.21% 7.45% 117,146 335.15 82.62 17.44 4.30 0.00 0.00 2.3400 0.58   35.76%   -16.38% 30-Sep-2015 3.95 1.18 22.65 1.69 4.42% 0.00% 26-Nov-2015 3.70 1.10 21.22 1.58 4.71% 0.00%
31-Dec-2015 19-Aug-2015 30-Jun-2015 2 264,343 20,956 15,048 15,049 5,857 268,264 38.92% 5.69% 5.61% 117,146 225.65 55.62 12.85 3.17 5.00 1.23 2.2900 0.56   78.18%   -11.59% 30-Jun-2015 4.02 1.78 31.29 1.76 3.20% 1.24% 19-Aug-2015 3.95 1.75 30.75 1.72 3.25% 1.27%
31-Dec-2015 20-May-2015 31-Mar-2015 1 140,064 11,880 8,446 8,446 - 268,264 - % 6.03% 3.15% 117,146 119.56 29.47 7.21 1.78 0.00 0.00 2.2900 0.56   -75.14%   -10.79% 31-Mar-2015 3.90 3.26 54.09 1.70 1.85% 0.00% 20-May-2015 3.95 3.30 54.79 1.72 1.83% 0.00%
31-Dec-2014 25-Feb-2015 31-Dec-2014 4 499,237 45,624 33,977 33,977 11,128 260,064 32.75% 6.81% 13.06% 117,146 426.17 105.05 28.91 7.15 9.50 2.34 2.2200 0.55   39.07%   12.79% 31-Dec-2014 3.58 0.84 12.34 1.61 8.10% 2.65% 25-Feb-2015 3.64 0.85 12.55 1.64 7.97% 2.61%
31-Dec-2014 18-Nov-2014 30-Sep-2014 3 375,932 32,953 24,432 24,432 4,100 249,520 16.78% 6.50% 9.79% 117,146 320.91 79.11 20.78 5.14 3.50 0.86 2.1300 0.53   43.53%   9.05% 30-Sep-2014 3.86 1.20 18.51 1.81 5.40% 0.91% 18-Nov-2014 3.70 1.15 17.74 1.74 5.64% 0.95%
31-Dec-2014 20-Aug-2014 30-Jun-2014 2 253,420 22,672 17,022 17,022 4,100 246,006 24.09% 6.72% 6.92% 117,146 216.33 53.33 14.48 3.58 3.50 0.86 2.1000 0.52   79.78%   6.89% 30-Jun-2014 3.80 1.76 26.15 1.81 3.82% 0.92% 20-Aug-2014 3.85 1.78 26.50 1.83 3.77% 0.91%
31-Dec-2014 21-May-2014 31-Mar-2014 1 130,927 12,622 9,468 9,468 - 244,601 - % 7.23% 3.87% 93,717 139.70 27.55 10.07 1.99 0.00 0.00 2.6100 0.51   -68.57%   3.90% 31-Mar-2014 4.60 3.29 45.53 1.76 2.20% 0.00% 21-May-2014 4.80 3.44 47.51 1.84 2.10% 0.00%
31-Dec-2013 26-Feb-2014 31-Dec-2013 4 418,451 40,615 30,122 30,123 9,373 235,264 31.12% 7.20% 12.80% 93,730 446.44 88.05 25.63 6.34 10.00 1.97 2.5100 0.50   34.45%   3.83% 31-Dec-2013 4.50 1.01 14.00 1.79 7.14% 2.22% 26-Feb-2014 4.40 0.99 13.69 1.75 7.30% 2.27%
31-Dec-2013 20-Nov-2013 30-Sep-2013 3 312,241 30,049 22,479 22,405 3,748 224,893 16.73% 7.20% 9.96% 93,705 333.22 65.70 23.91 4.71 4.00 0.79 2.4000 0.47   40.69%   6.07% 30-Sep-2013 4.80 1.44 20.08 2.00 4.98% 0.83% 20-Nov-2013 4.79 1.44 20.03 2.00 4.99% 0.84%
31-Dec-2013 21-Aug-2013 30-Jun-2013 2 210,561 21,470 15,967 15,925 3,749 223,081 23.54% 7.58% 7.14% 93,731 224.64 44.31 16.99 3.35 4.00 0.79 2.3800 0.47   74.75%   8.47% 28-Jun-2013 4.49 2.00 26.43 1.89 3.78% 0.89% 21-Aug-2013 4.95 2.20 29.13 2.08 3.43% 0.81%
31-Dec-2013 22-May-2013 31-Mar-2013 1 106,359 12,197 9,134 9,113 - 225,949 - % 8.59% 4.03% 93,755 113.44 22.38 9.72 1.92 0.00 0.00 2.4100 0.48   -68.59%   44.19% 29-Mar-2013 4.27 3.76 43.93 1.77 2.28% 0.00% 22-May-2013 4.37 3.85 44.96 1.81 2.22% 0.00%
31-Dec-2012 27-Feb-2013 31-Dec-2012 4 398,604 42,349 29,066 29,012 15,932 216,495 54.92% 7.29% 13.40% 93,720 425.31 83.88 30.96 6.10 17.00 3.35 2.3100 0.46   37.35%   3.60% 31-Dec-2012 3.68 0.87 11.89 1.59 8.41% 4.62% 27-Feb-2013 4.14 0.97 13.37 1.79 7.48% 4.11%
31-Dec-2012 21-Nov-2012 30-Sep-2012 3 302,611 32,431 21,168 21,122 5,622 208,033 26.62% 7.00% 10.15% 93,708 322.93 63.68 22.54 4.44 6.00 1.18 2.2200 0.44   43.86%   5.59% 28-Sep-2012 3.28 1.02 14.55 1.48 6.87% 1.83% 21-Nov-2012 3.56 1.10 15.79 1.60 6.33% 1.69%
31-Dec-2012 15-Aug-2012 30-Jun-2012 2 204,804 23,660 14,711 14,682 5,621 206,128 38.29% 7.18% 7.12% 93,694 218.59 43.10 15.67 3.09 6.00 1.18 2.2000 0.43   132.31%   -4.64% 29-Jun-2012 2.95 1.35 18.83 1.34 5.31% 2.03% 15-Aug-2012 3.11 1.42 19.85 1.41 5.04% 1.93%
31-Dec-2012 23-May-2012 31-Mar-2012 1 104,126 12,327 6,337 6,320 - 205,353 - % 6.09% 3.08% 93,768 111.05 21.91 6.74 1.33 0.00 0.00 2.1900 0.43   -77.43%   -28.78% 30-Mar-2012 2.94 2.65 43.62 1.34 2.29% 0.00% 23-May-2012 2.78 2.50 41.25 1.27 2.42% 0.00%
31-Dec-2011 23-Feb-2012 31-Dec-2011 4 366,002 35,778 28,397 28,004 14,524 199,598 51.87% 7.76% 14.03% 93,708 390.58 77.02 29.88 5.89 15.50 3.06 2.1300 0.42   39.99%   -14.99% 30-Dec-2011 2.74 0.70 9.17 1.29 10.91% 5.66% 23-Feb-2012 2.83 0.72 9.47 1.33 10.56% 5.48%
31-Dec-2011 15-Nov-2011 30-Sep-2011 3 273,672 26,464 20,405 20,004 5,155 190,269 25.77% 7.46% 10.51% 93,728 291.98 57.59 21.35 4.21 5.50 1.08 2.0300 0.40   29.92%   1.41% 30-Sep-2011 2.60 0.89 12.18 1.28 8.21% 2.12% 15-Nov-2011 2.84 0.97 13.31 1.40 7.51% 1.94%
31-Dec-2011 19-Aug-2011 30-Jun-2011 2 181,805 20,339 15,782 15,397 5,153 189,272 33.47% 8.68% 8.13% 93,699 194.03 38.26 16.43 3.24 5.50 1.08 2.0200 0.40   73.51%   23.14% 30-Jun-2011 3.05 1.57 18.56 1.51 5.39% 1.80% 19-Aug-2011 2.92 1.50 17.77 1.45 5.63% 1.88%
31-Dec-2011 19-May-2011 31-Mar-2011 1 92,822 11,601 9,115 8,874 - 190,200 - % 9.82% 4.67% 93,694 99.07 19.53 9.47 1.87 0.00 0.00 2.0300 0.40   -73.06%   32.37% 31-Mar-2011 2.90 2.93 30.62 1.43 3.27% 0.00% 19-May-2011 3.00 3.03 31.68 1.48 3.16% 0.00%
31-Dec-2010 24-Feb-2011 31-Dec-2010 4 313,718 45,094 38,340 32,941 12,183 182,745 36.98% 12.22% 18.03% 93,715 334.76 66.01 35.15 6.93 13.00 2.56 1.9500 0.38   66.99%   48.76% 30-Dec-2010 2.59 0.77 7.37 1.33 13.57% 5.02% 24-Feb-2011 2.68 0.80 7.62 1.37 13.12% 4.85%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  4 people like this.
 
NPRA1985 Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy.

-----------

US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said.

Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released.

The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said.

Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.

But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive."

https://www.globaltimes.cn/content/1206389.shtml
10/11/2020 11:54 PM
NPRA1985 Sinovac vaccine is not related to any companies in Malaysia but just wanted to share anyway.

------------
Brazilian politics, US pressure likely behind Chinese vaccine's suspension: experts

The Chinese Foreign Ministry, the Chinese vaccine producer and a Brazilian institute clarified that Brazilian health regulator's decision to halt trials of a Chinese-produced COVID-19 vaccine in Brazil is NOT RELATED TO THE VACCINE ITSELF, after foreign media said the suspension came following a "severe adverse event."

Chinese experts said politicization of vaccine issues by some Brazilian politicians was likely the reason. They said the vaccine trial issue, which is life-saving work amid the COVID-19 pandemic, should not be influenced by Brazilian political disputes or US pressure.

They stressed that the vaccine is essential to fight the virus, but the suspension without a reasonable excuse could slow down the vaccine-development process.

Wang Wenbin, spokesperson of the ministry, said at a press conference on Tuesday we notice that BUTANTAN INSTITUTE, partner of China's Sinovac Biotech in Brazil, has concluded that the reported "adverse event" that caused Brazil's health regulator on Monday to suspend trials of a Chinese-produced vaccine in Brazil was NOT RELATED TO THE VACCINE produced by Sinovac.

https://www.globaltimes.cn/content/1206393.shtml
11/11/2020 12:07 AM
serendipity89 https://www.theedgemarkets.com/article/apex-healthcare-ready-play-role-vaccine-distribution
11/11/2020 8:48 AM
JaBerry People jump to vaccine company. Do we realise without supply chain and logistics also problem? Apex play important roles and has facilities and temperature control in distributing the vaccine.
11/11/2020 9:52 AM
NPRA1985 China National Pharmaceutical Group Corp (SINOPHARM), a Chinese state-owned enterprise, announced on Wednesday that data from late-stage clinical trials for its Covid-19 vaccine are «BETTER THAN EXPECTED», Reuters reported.

In Morocco, Dr. Abdelhakim Yahyane, a member of the National Scientific Advisory Committee on Vaccination, told Yabiladi earier this week that vaccine trials in the country «have REACHED THE FINAL PHASE».

We are impatiently awaiting the end of this process, which could probably happen BY NEXT WEEK

https://en.yabiladi.com/articles/details/101544/conducted-morocco-among-others-sinopharm-s.html
13/11/2020 9:54 PM
Sinoboy If moderna vaccine is for real, apex health can play a substantial role. Apparently, moderna's vaccine requires storage of only -20C. This is exactly what apex health has, storage facilities that meet this requirement.
Hopefully, such important information is not lost on the public. This counter has great potential
16/11/2020 8:17 PM
Russell Eventually vaccine makers will need to come to Apex Healthcare for its cold chain facility which will be completed in Q4. It just completed it’s cold chain in Singapore. Perfect stock for the recovery trend
16/11/2020 9:13 PM
Sinoboy Hopefully today's uptrend can be maintained...
19/11/2020 6:13 PM
serendipity89 profit seems to have recovered back to pre covid level. next to see is after they completed their cold chain network, whehter they are able to secure distribution contract for the vaccine.
19/11/2020 7:46 PM
Mr.Sm Invest123 Apex Pharma

On 14th September, the Group’s wholly owned manufacturing subsidiary Xepa-Soul Pattinson (M) Sdn Bhd secured renewal of its GMP status with the National Pharmaceutical Regulatory Authority (‘NPRA’) through a scheduled desktop audit. In the quarter, Apex Pharma Marketing Pte Ltd in Singapore increased its cold chain distribution capabilities with the expansion of its current 2-8 degrees C cold room and the acquisition of a -20 degrees C freezer room for pharmaceuticals, vaccines and biologics. Expansion of cold chain distribution capacity in Malaysia is scheduled for completion before the end of the current financial year.
Review of Year To Date Performance versus Corresponding Period Last Year
20/11/2020 12:05 AM
20/11/2020 12:06 AM
DreamGuardian Up 8 sen
20/11/2020 12:06 AM
DreamGuardian Up 2.27%
20/11/2020 12:06 AM
DreamGuardian Okay also la
20/11/2020 12:07 AM
DreamGuardian Boleh juga la
20/11/2020 12:07 AM
DreamGuardian Keep surging
20/11/2020 12:07 AM
DreamGuardian Good luck
20/11/2020 12:07 AM
Mr.Sm Invest123 Tomorrow Fly over 4.50
20/11/2020 12:10 AM
Mr.Sm Invest123 Accumulating more
20/11/2020 12:20 AM
Sinoboy Looking good. Steady she goes, don't falter
20/11/2020 11:52 AM
chshzhd keep..
20/11/2020 4:59 PM
JaBerry Yes keep
23/11/2020 9:22 AM
NPRA1985 Post removed. Why?
23/11/2020 2:00 PM
JaBerry Waiting for vaccines come another distribution income.
27/11/2020 9:36 AM
mrmeow AHEALTH has the cold storage facility and has expanded by acquiring more cold facility and prepared for the covid19 vaccines. Don't foget this real making money one, supplying Msia and Singapore, stable & growing business even before covid, always on an uptrend
27/11/2020 9:41 AM
mrmeow Everyone looking for logistics company that has cold facility for vaccine distribution, yet they forget that this pharmaceutical company does distribution too and has the logistics capable of doing the real work
27/11/2020 12:00 PM
Mr.Sm Invest123 Vaccine-related: Following the approval of Budget 2021, vaccine-related companies will benefit under the Covid-19 fund/fill-and-finish process as well as distribution of vaccines once it is available in the future. Under this segment, SOLUTN, HWGB, BINTAI, DPHARMA, PHARMA, KANGER, -Ahealth, TITIJYA, MAHSING should be under traders radar.

Source: M+ Online
27/11/2020 12:47 PM
serendipity89 ''Apex has been approached by several manufacturers to be the authorised distributor for their upcoming Covid-19 vaccines (work-in-progress). There are many considerations in evaluating these proposals (ie. whether the products will be approved, pricings, efficiencies, requirements, etc) and hence, Apex has not committed to any manufacturer. Instead, the group will likely start off as a wholesaler, where Apex will distribute the Covid-19 vaccines from various manufacturers''

AffinHWang
28/11/2020 1:30 PM
NPRA1985 PM: No call to reject 2021 Budget just to bring about polls

"There is no need to do that (reject the 2021 Budget). If you ask me, I could have yesterday advised the Yang di-Pertuan Agong Al-Sultan Abdullah Ri'ayatuddin Al-Mustafa Billah Shah, to dissolve Parliament so that a general election can be held.

"But we all know that the problem is Covid-19. InsyaAllah, if He allows it, when the pandemic is over, we can hold a general election.

Muhyiddin added that the 2021 Budget, worth RM322.5 billion which was passed at the policy level in Parliament on Thursday, is aimed at easing the burden of the people and restoring the country's economy.

"I hope the 2021 Budget will be approved at the Dewan Rakyat and subsequently at the Dewan Negara. This is to ensure that the people will receive the assistance that they need during this tough time."

https://www.nst.com.my/news/politics/2020/11/645117/pm-no-call-reject-2021-budget-just-bring-about-polls
29/11/2020 9:25 PM
NPRA1985 No significant change to reject budget at committee level: Dr M

FORMER Prime Minister (PM) Tun Dr Mahathir Mohamad said no significant change can be achieved if the proposed Budget 2021 is rejected at the committee level debate session.

“Rejecting the budget at the committee level, as it is said to be done, will not bring any significant impact on the government nor the proposed budget.

“It is just an attempt to divert the criticisms of the people who are disappointed with the attitude of the Opposition,” Dr Mahathir said in a statement today.

https://themalaysianreserve.com/2020/11/27/no-significant-change-to-reject-budget-at-committee-level-dr-m/
29/11/2020 9:36 PM
weijuin1992 Buy on rumours sell on fact ,it had come so far with rumours ,once confirm news will fly ,sit in if you believe in good company !
01/12/2020 12:08 PM
weijuin1992 Reversal to uptrend on small fraction of price yet big indicator to this share as it is not so volatile like the others , good chance striking up again !
01/12/2020 5:39 PM
NPRA1985 U.K. Approves Pfizer Coronavirus Vaccine, a First in the West
The emergency approval, ahead of the United States and the European Union, clears the way for Britain to begin mass inoculations. “Help is on its way,” one official said.

https://www.nytimes.com/2020/12/02/world/europe/pfizer-coronavirus-vaccine-approved-uk.html
02/12/2020 6:36 PM
NPRA1985 Moderna Covid vaccine can get emergency authorisation approval in 2-3 days after panel meet: CEO

Moderna's vaccine candidate's full results from a late-stage study showed its vaccine was 94.1% effective with no serious safety concerns

https://www.livemint.com/news/world/moderna-covid-vaccine-can-get-emergency-authorisation-approval-in-2-3-days-after-panel-meet-ceo-11606922963960.html
03/12/2020 12:36 AM
NPRA1985 US says Covid-19 vaccines ready to be shipped nationwide immediately

https://www.freemalaysiatoday.com/category/world/2020/12/02/us-says-covid-19-vaccines-ready-to-be-shipped-nationwide-immediately/
03/12/2020 12:37 AM
NPRA1985 Janssen seeks Health Canada approval for its COVID-19 vaccine

https://www.cbc.ca/news/politics/johnson-johnson-health-canada-approval-1.5823173
03/12/2020 12:37 AM
NPRA1985 Johnson & Johnson has started a rolling submission with the European Medicines Agency (EMA) for its single-dose COVID-19 vaccine candidate.

https://www.biopharma-reporter.com/Article/2020/12/01/Johnson-Johnson-start-rolling-review-for-COVID-19-vaccine-in-Europe
03/12/2020 12:38 AM
NPRA1985 Promise of Covid vaccines is ‘phenomenal’, WHO says

https://www.freemalaysiatoday.com/category/world/2020/12/03/promise-of-covid-vaccines-is-phenomenal-who-says/
03/12/2020 10:25 PM
NPRA1985 Equities up as Covid-19 cases drop, vaccine news spurs economic recovery bets

https://www.theedgemarkets.com/article/fbm-klci-closes-2954-points-162826
03/12/2020 10:47 PM
NPRA1985 DUBAI: Bahrain said on Friday it has granted emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, becoming the second country after Britain to approve it.

The kingdom had also approved Sinopharm’s COVID-19 vaccine in November for use by frontline workers.

https://www.arabnews.com/node/1772516/middle-east
05/12/2020 1:33 AM
NPRA1985 South Korea reaches deal to buy AstraZeneca's Covid-19 vaccine candidate

https://www.straitstimes.com/asia/east-asia/south-korea-reaches-deal-to-buy-astrazenecas-covid-19-vaccine-candidate
05/12/2020 1:46 AM
NPRA1985 500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/
05/12/2020 2:34 PM
NPRA1985 UAE says Sinopharm vaccine has 86% efficacy against COVID-19

DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.

The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.

The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.

“The analysis shows no serious safety concerns,” it said.

It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.

https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V
09/12/2020 3:12 PM
NPRA1985 United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19

TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.

The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.

The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.

The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”

The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.

https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c
09/12/2020 10:25 PM
NPRA1985 Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/
10/12/2020 11:55 PM
NPRA1985 FDA intends to 'proceed towards an authorization' of Covid-19 vaccine, official says, as cases soar

(CNN)The FDA has informed Pfizer it intends "to proceed towards an authorization" of the manufacturer's Covid-19 vaccine, the US Health and Human Services Secretary told ABC on Friday morning, as the country is deep into a worsening health crisis.

The statement comes a day after an FDA panel recommended the agency grant an emergency use authorization for the Pfizer-BioNTech coronavirus vaccine.Other key steps remain, but if those hurdles are cleared, the first vaccinations in the US could happen early next week, HHS Secretary Alex Azar told ABC's George Stephanopoulos.

"The FDA informed Pfizer that they do intend to proceed toward an authorization for their vaccine," Azar told ABC Friday morning.

https://edition.cnn.com/2020/12/11/health/us-coronavirus-friday/index.html
12/12/2020 2:26 AM
NPRA1985 Pfizer Vaccine Cleared in U.S., a Landmark in Covid-19 Fight

Pfizer Inc. gained emergency U.S. authorization for its Covid-19 vaccine on Friday, completing an unprecedented scientific sprint that could eventually help bring an end to a pandemic that has killed nearly 300,000 Americans

https://www.bloomberg.com/news/articles/2020-12-12/pfizer-covid-vaccine-wins-u-s-fda-emergency-use-authorization
12/12/2020 3:04 PM
NPRA1985 Bursa Malaysia is expected to trend higher next week

https://www.malaymail.com/news/money/2020/12/12/bursa-malaysia-is-expected-to-trend-higher-next-week/1931258

----------------

Bursa Malaysia expected to break 1,700 psychological level

Bursa Malaysia is expected to trend higher next week, with the key FTSE Bursa Malaysia KLCI (FBM KLCI) breaking the psychological level of 1,700, and poised to march into the new year with a big bang.

https://themalaysianreserve.com/2020/12/12/bursa-malaysia-expected-to-break-1700-psychological-level/
12/12/2020 6:05 PM
FT1981 this counter not active?
07/01/2021 11:19 AM
FT1981 https://app.sinchew.com.my/content/content_2406317.html?type=detail&fileId=2406317&colID=6660
07/01/2021 11:20 AM